Eli Lilly (LLY) Non Operating Income (2009 - 2026)

Eli Lilly (LLY) has reported Non Operating Income for 18 consecutive years, with -$65.0 million the latest figure, recorded in Q1 2026.

• Non Operating Income for Q1 2026 came in at -$65.0 million, up 72.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$397.0 million (up 18.16% YoY), and the FY2025 annual result was -$571.0 million, down 160.73% from the prior year.
• Non Operating Income was -$65.0 million for Q1 2026 at Eli Lilly, up from -$108.3 million in the prior quarter.
• Over five years, Non Operating Income peaked at $260.0 million in Q4 2022 and troughed at -$350.7 million in Q1 2022.
• Average Non Operating Income over 5 years is -$63.5 million, with a median of -$90.6 million recorded in 2025.
• Year-over-year, Non Operating Income surged 436.35% in 2022 and plunged 981.92% in 2025.
• Over 5 years, Non Operating Income stood at $260.0 million in 2022, then plunged by 53.35% to $121.3 million in 2023, then tumbled by 191.1% to -$110.5 million in 2024, then climbed by 1.99% to -$108.3 million in 2025, then soared by 39.98% to -$65.0 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were -$65.0 million in Q1 2026, -$108.3 million in Q4 2025, and -$133.1 million in Q3 2025.